Poster Presentations: Tuesday, October 25, 2011 |

Ku70 Small Interfering RNA Sensitizes Cisplatin-Resistant Human Lung Adenocarcinoma A549/DDP Cell to Cisplatin FREE TO VIEW

Jie Zhang, PhD; Ke Wang, PhD; Ping Li, MD; Yarong Li, PhD
Chest. 2011;140(4_MeetingAbstracts):316A. doi:10.1378/chest.1117384
Text Size: A A A
Published online


PURPOSE: Ku70 protein is involved in DNA double-strand break repair,V(D)J recombination and chemoresistance. In this study, we investigated the role of Ku70 in the chemoresistance of lung cancer and the potential of Ku70 small-interfering RNA (siRNA) as a therapy for reversal of cisplatin resistance.

METHODS: Ku70 mRNA and protein expression levels were investigated by reverse transcription PCR and western blot analyses, respectively. Ku70-specific siRNA was synthesized and transfected into cisplatin-resistant human lung adenocarcinoma cell line A549/DDP prior to treatment with cisplatin. Cell survival was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Apoptosis was assessed using flow cytometry analysis. Caspase-3 activity was detected by spectrophotometer.

RESULTS: The Ku70mRNA and protein expression were significantly elevated in A549DDP cells compared with those in parental A549 cells. Ku70-specific siRNA enhanced the sensitivity of A549/DDP cells to cisplatin, along with increased activity of caspase-3,increased cell apoptosis, declined mitochondrial membrane potential and arrested S phase of cell cycle.

CONCLUSIONS: Ku70 might be involved in the chemoresistance of lung cancer.Ku70-specific siRNA induced sensitivity to cisplatin treatment in cisplatin-resistant A549/DDP cells and increased cell apoptosis was invovled.

CLINICAL IMPLICATIONS: Ku70 may be one marker of chemoresistance for lung cancer.Combination treatment with Ku70 siRNA and cisplatin may overcome cisplatin resistance and enhance therapeutic efficacy.

DISCLOSURE: The following authors have nothing to disclose: Jie Zhang, Ke Wang, Ping Li, Yarong Li

No Product/Research Disclosure Information

09:00 AM - 10:00 AM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543